Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Intellia Therapeutics Inc’s stock clocked out at $12.5, down -4.65% from its previous closing price of $13.11. In other words, the price has decreased by -$4.65 from its previous closing price. On the day, 4.9 million shares were traded. NTLA stock price reached its highest trading level at $13.19 during the session, while it also had its lowest trading level at $12.2812.
Ratios:
To gain a deeper understanding of NTLA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 23 ’25 when Dulac Edward J III sold 7,462 shares for $14.02 per share. The transaction valued at 104,617 led to the insider holds 106,062 shares of the business.
Clark Eliana sold 1,022 shares of NTLA for $10,036 on Jul 01 ’25. The EVP, Chief Technical Officer now owns 95,369 shares after completing the transaction at $9.82 per share. On Jul 02 ’25, another insider, Dube Michael P, who serves as the VP, Chief Accounting Officer of the company, sold 2,503 shares for $9.95 each. As a result, the insider received 24,905 and left with 57,137 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1294787456 and an Enterprise Value of 910298432. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.41 while its Price-to-Book (P/B) ratio in mrq is 1.66. Its current Enterprise Value per Revenue stands at 19.976 whereas that against EBITDA is -1.715.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.35, which has changed by -0.5230828 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $27.27, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 24.32%, while the 200-Day Moving Average is calculated to be 11.36%.
Shares Statistics:
It appears that NTLA traded 4.85M shares on average per day over the past three months and 4962440 shares per day over the past ten days. A total of 103.54M shares are outstanding, with a floating share count of 97.43M. Insiders hold about 5.94% of the company’s shares, while institutions hold 92.18% stake in the company. Shares short for NTLA as of 1752537600 were 28867302 with a Short Ratio of 5.95, compared to 1749772800 on 29689496. Therefore, it implies a Short% of Shares Outstanding of 28867302 and a Short% of Float of 31.72.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Intellia Therapeutics Inc (NTLA) is currently under the scrutiny of 23.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.54 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$2.38 and -$5.06 for the fiscal current year, implying an average EPS of -$4.14. EPS for the following year is -$3.85, with 27.0 analysts recommending between -$1.1 and -$5.31.
Revenue Estimates
A total of 27 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $16.63M, resulting in an average revenue estimate of $56.04M. In the same quarter a year ago, actual revenue was $57.88M
